CD8A and neoplasm: However, upregulation of miR-155 in tumor-specific CD8+ T cells may circumvent the possible adverse effects on immune responses driven by systemic injection of miR-155 inhibitors, leading to enhanced T-cell-based adaptive treatment (81).